Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ipsen and BioMérieux Enter Into a Broad Partnership in Personalized Medicine

Published: Friday, March 11, 2011
Last Updated: Friday, March 11, 2011
Bookmark and Share
The two companies leverage combined expertise in therapeutics and in diagnostics to improve patient care.

Ipsen and bioMérieux announced that they have entered into a partnership to create a global collaboration in theranostics, with a focus on hormone-dependent cancers. The two companies have signed a framework agreement to leverage their expertise and resources to develop a personalized approach to medicine based on Ipsen’s broad portfolio of innovative compounds and bioMérieux’s diagnostic tests.

Both companies will jointly identify programs that would benefit from the co-development of a therapeutic and a companion diagnostic test, notably in the prevention and treatment of prostate and breast cancers, neuro-endocrine tumors (NETs) and pituitary tumors.

This novel partnership emphasizes Ipsen’s and bioMérieux’s expertise in the emerging field of personalized medicine, a concept based on the systematic use of individual patient molecular information to tailor specific preventive and therapeutic solutions. The early development of companion diagnostic tests and innovative compounds may accelerate early clinical proof of concept and support the registration of Ipsen clinical drug candidates.

“We are very pleased to build this partnership with Ipsen, which has developed over the years a significant scientific and medical expertise. Our goal is to reinforce personalized medicine and contribute through this partnership to the novel paradigm in medicine, which is increasingly “patient-driven” rather than “diseasedriven”,” said Prof. Christian Bréchot, Vice President of Institut Mérieux, in charge of medical and scientific affairs, and member of the bioMérieux board.

Dr. Claude Bertrand, Executive Vice President, Chief Scientific Officer of Ipsen stated: “We are delighted to accelerate the deployment of our personalized medicine programs in oncology through this broad partnership with bioMérieux”. Claude Bertrand added: “The shared vision and the cross-company synergies represent a unique opportunity to leverage early stage co-development of innovative products and biomarkers for patient care.”

Theranostics, the development of innovative therapeutic agents with diagnostic companion tests (taking into account an individual’s genetics or tumor molecular profile) may be key to improve treatment efficacy and safety through the identification of potential responding patients as well as in monitoring the response to a treatment. The creation of the Ipsen / bioMérieux partnership reflects the visionary convergence of medical and information technologies to serve individual patient’s needs.

Theranostics offers a cutting-edge solution to optimize healthcare by making sure the best medicine is available to the right patients. It may also accelerate the time to market of new compounds through an improved selection of patients enrolled in clinical trials, thereby helping to address the global challenge of R&D productivity.

bioMérieux is committed to making personalized medicine a reality by building partnerships to develop theranostics for infectious diseases, cancer and cardiovascular diseases. Some collaborations include Ipsen, Merck & Co. and GSK.

bioMérieux has made a sustained investment in high medical value biomarkers through in-house R&D programs, licensing and research collaborations. Theranostics development also leverages bioMérieux's unique hybrid business strategy: the high complexity CLIA lab of its subsidiary, bioTheranostics, allied with bioMérieux's global IVD business, supports aggressive development timelines while ensuring test availability wherever the drug is sold.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
R&D Agreement for Development of CtDNA Diagnostics
SeraCare and NIST partner for development of ctDNA diagnostic assay reference materials.
Adipose Analysis on Microfluidic Chips
Scientists have developed a microfluidic chip the works with minute liquid quantities to grow and study cells.
New Device can Study Electric Field Cancer Therapy
Microfluidic device allows study of electric field cancer therapy through low-intensity fields, preventing malignant cells spreading.
DNA Production Facility Begins Operation
Scientists mark the opening of the UK's first fully automated DNA construction and modification facility.
A “Micro Winery” That Makes Wine Continuously
An American professor, working in collaboration with EPFL, is developing a miniature device for producing wine non-stop and testing different fermentation processes.
Testing for Malaria or Cancer at Home
Chemist develops tech to save lives in rural Africa.
Tough New Hydrogel Hybrid Doesn’t Dry Out
Water-based material could be used to make artificial skin, longer-lasting contact lenses.
Lasers Carve the Path to Tissue Engineering
A new technique, developed at EPFL, combines microfluidics and lasers to guide cells in 3D space, overcoming major limitations to tissue engineering.
A Future Tool for Medicine, Food Safety
A new type of electronic sensor that might be used to quickly detect and classify bacteria for medical diagnostics and food safety has passed a key hurdle by distinguishing between dead and living bacteria cells.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!